Cascadian Therapeutics Inc. (CASC)
|Super Investor Stats:|
|% of all portfolios:||0.004%|
|Total insider Buys/Sells last 3 months:|
Open Market Insider Buys
|Date Filed||Reporting Name||Relationship||Trans. Date||Shares||Price $||Total Value $|
|04 Apr 2017||MYERS SCOTT DUNSETH||President and CEO||31 Mar 2017||2,000||4.11||8,229|
|30 Mar 2017||FYFE GWEN A.||Director||28 Mar 2017||1,666||4.12||6,857|
|21 Mar 2017||MYERS SCOTT DUNSETH||President and CEO||20 Mar 2017||1,000||3.93||3,927|
|03 Feb 2017||LOVE TED W||Director||02 Feb 2017||23,000||4.24||97,520|
|01 Feb 2017||HENNEY CHRISTOPHER S||Director||30 Jan 2017||25,324||4.11||103,973|
|31 Jan 2017||MYERS SCOTT DUNSETH||President and CEO||27 Jan 2017||20,500||3.76||77,039|
|18 Aug 2016||MYERS SCOTT DUNSETH||President and CEO||17 Aug 2016||45,000||1.15||51,746|
|28 Jun 2016||MYERS SCOTT DUNSETH||President and CEO||28 Jun 2016||62,500||0.80||50,000|
* "Hold Price" is the term we use to indicate the price at which our Super Investors are comfortable owning a security. It is the price of the security as of the portfolio date (usually quarter end). It's a reasonable indicator of a stock's undervaluation at that price, otherwise it would have been sold. We only provide this value when a security is owned by at least two Super Investors. In the case of reporting dates being different, we calculate a weighted average price.
* Open Market Insider Buys refer to transactions where insiders purchase shares of their own company in the open market in the same way an investor would do. These tend to be far more indicative of insiders' confidence in the company than other forms of acquiring shares such as stock grants, gifts, or exercising of stock options.
* Please note: Occasionally multiple forms are filed for the same transaction - for example several beneficiaries reporting the same transaction. In such situations, we only show a single entry. For a complete list of insider filings click on the insider link immediately above the ownership table.
* P = Preferred Stock